Vitamin D and Protein for Sarcopenia: What Trials Show

Vitamin D will not reverse diagnosed sarcopenia on its own. In the most clinically specific randomized-trial review available, researchers could not find enough vitamin D monotherapy trials in people with confirmed sarcopenia to pool an independent effect on strength, muscle mass, or physical performance.

Adding protein changes part of that picture. A vitamin D-plus-protein regimen improved handgrip and chair-stand performance in pooled trials, but it did not reliably increase appendicular lean mass, skeletal muscle index, or walking speed. The useful conclusion is narrower than the supplement aisle implies: correct vitamin D deficiency, eat enough protein, and do progressive resistance training. Supplements can support that plan; they have not replaced the loading stimulus that muscle needs.

This evidence applies to diagnosed sarcopenia

That distinction matters. Many nutrition studies enroll generally healthy older adults, people at risk of frailty, or mixed clinical populations. The 2021 Gkekas et al. systematic review and meta-analysis restricted its analysis to randomized controlled trials in people who met EWGSOP or AWGS sarcopenia criteria: low muscle mass plus low strength or poor physical performance. Eight trials, totaling 776 participants, qualified.

That is a small evidence base, but it asks the right clinical question. Sarcopenic muscle is often less responsive to nutrition alone than healthy muscle. Results in a broad older-adult population therefore cannot simply be pasted onto someone who already has a formal diagnosis.

Vitamin D alone has no poolable trial case

Gkekas and colleagues could not pool a vitamin D-only comparison because too few randomized trials in diagnosed sarcopenia measured its independent effects. That is not evidence that vitamin D has zero effect. It means the trial literature does not establish a dependable standalone effect in this population.

A 2021 network meta-analysis by Cheng et al. reached a compatible conclusion through indirect comparisons: vitamin D alone did not rank competitively against combination interventions for functional outcomes. Network meta-analysis can compare treatments that have not always faced each other in the same trial, but those comparisons depend on whether the studies are similar enough to compare. It adds context; it does not solve the shortage of direct monotherapy trials.

Vitamin D still has a legitimate role when a clinician identifies deficiency. The point is practical, not anti-vitamin: treating deficiency for bone and general health is sensible, while expecting vitamin D to rebuild muscle without protein and training is unsupported.

Protein plus vitamin D improves some functional outcomes

In the Gkekas meta-analysis, vitamin D doses ranged from 100 to 1,600 IU per day and supplemental protein ranged from 10 to 44 g per day. The combination improved handgrip strength with a standardized mean difference (SMD) of 0.38 (95% CI, 0.18 to 0.47; p=0.04). It also improved sit-to-stand performance, SMD 0.25 (95% CI, 0.06 to 0.43; p=0.007).

The chair-stand result deserves more confidence than the grip estimate. Its heterogeneity was 0%, meaning the included trials gave highly consistent results by that statistic. Handgrip heterogeneity was 76.2%, which means trial results varied substantially. The pooled grip result was statistically significant, but it may not describe what a particular patient or clinic should expect.

These are functional endpoints, not trivial laboratory curiosities. Better chair-stand performance and grip strength can matter for rising from a chair, carrying objects, and maintaining independence. Still, standardized mean differences do not translate automatically into a known reduction in falls, disability, hospitalization, or mortality. The trials measured performance, not those downstream outcomes.

The combination did not reliably restore muscle mass

The same analysis found no statistically significant improvement in the mass-related outcomes that many people hope supplements will change. Skeletal muscle index was borderline and non-significant: SMD 0.25, 95% CI −0.006 to 0.51, p=0.05. Appendicular lean mass also did not reach statistical significance, and walking speed did not improve.

This pattern sets a boundary on the claim. Vitamin D plus protein at the doses and durations studied can improve selected strength-related measures. It has not reliably restored measurable muscle mass. DEXA and bioimpedance can miss small changes, especially over short periods, but a null result across these endpoints remains a result, not an administrative inconvenience.

Most interventions lasted 12 weeks or less. That may be too short for anabolically resistant muscle to gain enough lean tissue to clear a measurement threshold. The trials also varied in protein source, including whey, casein, and mixed formulas. Those differences make an average effect harder to interpret.

Protein supplies the anabolic signal, but leucine is not a shortcut

The biology and the trial pattern both point toward protein as the primary nutritional driver. A 2023 meta-analysis by Nasimi et al. assessed whey protein with or without vitamin D on sarcopenia-related measures and described whey protein, including its leucine content, as the ingredient that stimulates muscle protein synthesis. A separate 2023 review by Chang et al. examined whey protein, leucine, and vitamin D in patients with sarcopenia and likewise found functional benefits from the combined formulation.

Neither pooled analysis can cleanly assign every observed effect to leucine, protein, or vitamin D when they were delivered together. Leucine can activate mTORC1 signaling involved in muscle protein synthesis, and a 2022 meta-analysis of 17 randomized trials by Guo et al. provides useful context in older adults broadly. But that population was not limited to diagnosed sarcopenia.

More pointedly, a 2025 meta-analysis by Huang et al. found inconsistent, unreliable muscle-mass effects from leucine supplementation in older adults with sarcopenia. A leucine-enriched shake may be reasonable nutrition; it is not a guaranteed way around anabolic resistance.

The plausible explanation for the null mass findings is not a verdict: the trials may have used too little protein, run too briefly, omitted resistance training, or encountered a true ceiling for supplements alone. Existing trials cannot separate those possibilities.

Resistance training changes the hierarchy

Protein doses in the Gkekas trials—10 to 44 g per day—were below nutritional targets commonly discussed for sarcopenic older adults in the 2023 systematic review by Cochet et al.. Underfeeding protein could help explain why muscle mass did not change, but that explanation is post-hoc. It needs trials that deliberately compare adequate protein doses, protein types, and exercise plans.

There is a stronger reason not to treat higher-dose protein as the entire answer: resistance training repeatedly ranks above supplementation-only strategies. A 2024 review by Li et al. found that whey protein without resistance training had limited effects on muscle mass in sarcopenic populations. The evidence points to mechanical loading as the missing stimulus, not simply another scoop of powder.

Several later network meta-analyses reached the same broad ranking. The 2025 analyses by Wei et al., Fu et al., and Zhao et al. ranked resistance-training-inclusive approaches highest across muscle mass, handgrip, and physical-performance outcomes. Zhao et al. is especially relevant because it used EWGSOP/AWGS diagnostic criteria. These are indirect comparisons, so they cannot substitute for a single head-to-head trial of training, supplements, and both together. Yet their agreement with the direct whey-plus-training evidence is hard to ignore.

A 12-week multicenter randomized trial in 110 older adults with sarcopenia or possible sarcopenia adds a practical example. In the Sun et al. trial, the intervention combined daily muscle-targeted nutrition with a structured program that included twice-weekly resistance training. The study reported improvements in proxy measures of muscle mass, strength, and function. Because nutrition and exercise were bundled, it cannot tell us how much each component contributed. It does show that a combined program can be delivered over 12 weeks.

What to do with this evidence

For a person with clinician-confirmed sarcopenia, vitamin D alone should not be the treatment plan. Check and correct deficiency as clinically appropriate, but do not expect it to independently rebuild muscle.

Protein plus vitamin D may improve chair-stand performance and possibly grip strength, although the grip result varies markedly across trials. The combination has not reliably increased muscle mass or walking speed at the studied doses and follow-up periods. Protein adequacy matters, but the evidence does not identify one proven dose, formula, leucine level, or vitamin D dose for every patient.

The priority is progressive, structured resistance training tailored to the person’s health status and capacity, alongside adequate dietary protein and vitamin D deficiency treatment when indicated. Sarcopenia is a medical diagnosis with fall, frailty, and comorbidity considerations, so a clinician and qualified exercise professional should help shape that plan. The current evidence gives supplements a supporting role. The training provides the signal that muscle has been waiting for.